IN A PRELIMINARY report1 we indicated that quinacrine hydrochloride (atabrine) has a definite place in the treatment of patients with lupus erythematosus—especially in those with the chronic discoid variety. We wish now to report on our additional experience and longer observation of the patients treated.
Apparently the English-speaking world first became aware of the value of quinacrine in the treatment of patients with lupus erythematosus from the report of Page,2 although such therapy had been described 10 years earlier by Prokoptchouk,3 Sorinson,4 Popoff and Kutintscheff,5 and Ottolenghi and Lodigiani.6 During the past year the case presentations at society meetings and a few reports in the literature* indicate general agreement that quinacrine is an efficient drug for the treatment of chronic discoid lupus erythematosus.
Prokoptchouk3 successfully treated 35 patients with lupus erythematosus by giving 100 mg. of quinacrine hydrochloride three times daily
ROBERT R. KIERLAND, LOUIS A. BRUNSTING, PAUL A. O'LEARY. QUINACRINE HYDROCHLORIDE (ATABRINE) IN THE TREATMENT OF LUPUS ERYTHEMATOSUS. AMA Arch Derm Syphilol. 1953;68(6):651–663. doi:10.1001/archderm.1953.01540120035006